Want to see STE full AI Analyst Report?
STE Stock Chart & Stats
$236.44
$3.43(1.63%)
At close: 4:00 PM EDT
$236.44
$3.43(1.63%)
Day’s Range― - ―
52-Week Range$195.14 - $269.44
Previous CloseN/A
Volume511.42K
Average Volume (3M)696.18K
Market Cap
$22.79B
Enterprise Value$22.19K
Total Cash (Recent Filing)$482.30M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)28.4
Beta0.38
Next Earnings
Nov 11, 2026EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend Yield1.08%
Share Statistics
EPS (TTM)8.20
Shares Outstanding97,500,110
10 Day Avg. Volume572,556
30 Day Avg. Volume696,181
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$271.33Price Target Upside14.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)11.2
Revenue Forecast (FY)$6.38B
Bulls Say, Bears Say
Bulls Say
Installed-base Recurring RevenueSTERIS combines capital equipment with repeat consumables, service contracts and outsourced sterilization. This installed-base model supports customer retention, recurring revenue and durable demand across regulated healthcare and life-science workflows.
Sustained Growth And ProfitabilityConsistent revenue expansion, healthy mid-40% gross margins and improving profitability indicate pricing power and operating leverage. FY2027 guidance for 7–8% revenue growth and roughly 50 basis points of EBIT margin expansion supports continued fundamental progress.
Conservative Balance Sheet And Cash GenerationVery low leverage gives STERIS financial flexibility to invest, pursue tuck-in acquisitions and return capital without excessive balance-sheet risk. Strong operating cash flow and substantial free cash flow also provide internal funding for growth and shareholder distributions.
Bears Say
Persistent Tariff And Input-cost ExposureTariffs remain an embedded cost in the outlook rather than a one-quarter disruption, while STERIS also faces freight, energy, metals, plastics and chemical inflation. These pressures can limit margin expansion and require sustained pricing or productivity gains.
Lower Forecast Free Cash FlowThe projected cash-flow decline reflects higher working capital needs, incentive payments, settlement payments and approximately $375 million of capital expenditure. Lower conversion temporarily reduces funding flexibility for acquisitions, investment and shareholder returns.
Restructuring And AST Demand PressureMed-tech customers reducing inventories and softer AST services create execution and forecasting risk, while facility consolidation adds multiyear restructuring costs. The changes may improve efficiency eventually but can weigh on margins and cash flow during implementation.
Steris News
STE FAQ
What was Steris plc’s price range in the past 12 months?
Steris plc lowest stock price was $195.14 and its highest was $269.44 in the past 12 months.
What is Steris plc’s market cap?
Steris plc’s market cap is $22.79B.
When is Steris plc’s upcoming earnings report date?
Steris plc’s upcoming earnings report date is Nov 11, 2026 which is in 70 days.
How were Steris plc’s earnings last quarter?
Steris plc released its earnings results on Aug 05, 2026. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.495 by $0.095.
Is Steris plc overvalued?
According to Wall Street analysts Steris plc’s price is currently Undervalued.
Does Steris plc pay dividends?
Steris plc pays a Quarterly dividend of $0.69 which represents an annual dividend yield of 1.08%. See more information on Steris plc dividends here
What is Steris plc’s EPS estimate?
Steris plc’s EPS estimate is 2.68.
How many shares outstanding does Steris plc have?
Steris plc has 97,500,110 shares outstanding.
What happened to Steris plc’s price movement after its last earnings report?
Steris plc reported an EPS of $2.59 in its last earnings report, beating expectations of $2.495. Following the earnings report the stock price went down -0.4%.
Which hedge fund is a major shareholder of Steris plc?
Currently, no hedge funds are holding shares in STE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$271.33 (14.76% Upside)
$271.33 (14.76% Upside)
Blogger Sentiment
Bullish
STE Sentiment 63%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 23.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.79%
12-Months-Change
Fundamentals
Return on Equity
1.08%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Steris plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
STE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all STE earnings summariesSTE Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
STE Stock 12 Month Forecast
Average Price Target
$271.33
▲(14.76% Upside)
Technical Analysis
Ownership Overview
0.29% Insiders
28.43% Mutual Funds
18.64% Other Institutional Investors
23.54% Public Companies and
Individual Investors